In contrast, Novartis announced positive Phase III results for Remibrutinib in treating relapsing multiple sclerosis (MS). The oral drug significantly outperformed Sanofi's Aubagio by reducing relapse rates, brain lesions, and disability progression with no signs of liver toxicity.